



Neuroendocrine Tumors: From Diagnosis to Therapy

Guest Editors:

Dr. Damiano Caruso

Prof. Dr. Francesco Panzuto

Dr. Daniela Prosperi

Dr. Michela Polici

Message from the Guest Editors

Neuroendocrine neoplasms are considered rare tumors with a wide spectrum of behaviors, mainly indolent, but are highly dependent on the presence of high-risk clinical features. Diagnoses, using a dual morphological and functional approach in NENs, are based on histology and imaging.

However, from the limited tissue sampling, in the case of tumor biopsy, to the bias linked to the subjective assessment of medical images. Furthermore, based on the assessment of response to therapy, the morphological RECIST 1.1 criteria could be reductive and not appropriate. In this context, quantitative imaging has acquired relevance as a supporting tool for clinicians in order to overcome the limits associated with the conventional approach, especially in prediction prognosis and in response to therapy. Thus, to outline a structured therapeutic path, one of the future landscapes of NEN management may be the integration of quantitative imaging with conventional evaluations.

This Special Issue will highlight the main strengths and limitations in the management of NENs, from the diagnosis to the response to therapy, and will investigate the emerging role of quantitative biomarkers.





cancers



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (*Oncology*) / CiteScore - Q1 (*Oncology*)

Contact Us

Cancers Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
X@Cancers_MDPI